Influenza A virus (H1N1) 2009 pandemic vaccine (H1N1pdm09 vaccine)

This entry refers to the vaccines developed for the 2009 H1N1 influenza pandemic, which are frequently categorized in databases like ChEMBL as having no discrete drug–target interaction because they stimulate a systemic immune response rather than binding to a single molecular target (ChEMBL Database). These vaccines utilize antigens from the A/California/07/2009 (H1N1)v-like virus, primarily the hemagglutinin and neuraminidase proteins, to induce active immunity (CDC, 2009). The mechanism involves the activation of B-cells to produce neutralizing antibodies and the priming of T-cells to recognize viral components (WHO, 2010). Clinical formulations included inactivated, adjuvanted, and live-attenuated vaccines such as Pandemrix and Focetria. While effective in controlling the pandemic, certain formulations were linked to rare safety concerns, most notably an increased incidence of narcolepsy associated with the AS03-adjuvanted Pandemrix vaccine in Europe (Taba et al., 2013; Partinen et al., 2012). Additionally, like other influenza vaccines, there was a monitored risk for Guillain-Barré syndrome (Salmon et al., 2013). Because the vaccine's efficacy depends on a complex biological cascade involving multiple cell types and signaling pathways, it does not possess a discrete protein target in the traditional pharmacological sense.

Other names

2009 H1N1 vaccineSwine flu vaccineA(H1N1)pdm09 vaccinePandemic influenza vaccineH1N1v vaccine

Induction of active immunity through the presentation of viral hemagglutinin and neuraminidase antigens to stimulate B-cell and T-cell responses.